PGENPrecigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious di…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Reasons Why Investors Should Consider Betting on PGEN Stock Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential. | ||
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers. | ||
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis. | ||
 Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
 Can Precigen (PGEN) Justify Its Valuation On Earnings And PAPZIMEOS Launch? Why Precigen’s latest earnings matter for investors Precigen (PGEN) drew fresh attention after its second quarter 2026 earnings, where revenue reached US$54.98 million and net income came in at US$20.07 million, following the commercial launch of PAPZIMEOS. See our latest analysis for Precigen. Precigen’s latest earnings arrived alongside strong share price momentum, with a 30 day share price return of 28.95% and a 90 day share price return of 65.30%. The 1 year total shareholder return of... | ||
 Precigen (PGEN) Q2 2026 Earnings Call Transcript PAPZIMEOS revenue surged 145.8% sequentially as company posts first profitable quarter. | ||
 Precigen, Inc. Q2 2026 Earnings Call Summary Moby summary of Precigen, Inc.'s Q2 2026 earnings call | ||
Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved Precigen Inc (PGEN) reports exceptional Q2 2026 with $53.1 million in Papsimios revenue, driving the company to quarterly profitability ahead of its first FDA approval anniversary. | ||
 Precigen Q2 Earnings Call Highlights Precigen (NASDAQ:PGEN) reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy’s August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP. PAPZIMEOS revenue total | ||
 Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates Precigen (PGEN) delivered earnings and revenue surprises of +350.00% and +97.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors? Focused on gene and cellular therapies, this biotech firm reported a notable insider sale amid a year of rapid share price gains. | ||
IInsider Monkey | ||
IInsider Monkey | ||
IInsider Monkey | ||